Denosumab treatment of giant cell tumors in the spine induces woven bone formation.

ABSTRACT: Giant cell tumors of bone (GCTB) are rare but aggressive, locally destructive tumors. They typically affect young people, significantly reducing their quality of life and increasing mortality rates. Giant cell tumors of bone are composed of osteoclast-like giant cells that respond to increased secretion of RANKL by stromal cells, triggering osteolysis. For over a decade, denosumab, a monoclonal antibody targeting this receptor activator, has been approved as a neo-adjuvant to facilitate surgical resection or in the setting of inoperable tumors. Denosumab treatment has shown rapid pain improvement and tumor size reduction in the spine. Although variable degrees of tumor mineralization have been observed in clinical applications of this drug, the nature of this newly formed mineralized tissu

SUBMITTER: Birch R 

PROVIDER: S-EPMC12087960 | biostudies-literature | 2025 Jun

REPOSITORIES: biostudies-literature